{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-022704","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2026-05-13T20:01:30+00:00","discovered_at":"2026-05-13T20:02:00.679633+00:00","generated_at":"2026-05-13T20:02:50.753578+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Mira Pharmaceuticals announces positive Phase 1 results for Ketamir-2; plans Phase 2a in CIPN","bullets":["Phase 1 trial in 57 healthy volunteers; all completed with no withdrawals or serious adverse events.","Ketamir-2 half-life 2.5–7 hours; active metabolite nor-Ketamir-2 half-life 7–9 hours; supports once-daily dosing.","DEA classified Ketamir-2 as not a controlled substance, eliminating scheduling barriers.","Company preparing Phase 2a protocol for chemotherapy-induced peripheral neuropathy (CIPN) for FDA submission.","Preclinical data showed Ketamir-2 superior efficacy vs. ketamine, pregabalin, and gabapentin in neuropathic pain models."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-022704","json":"https://secwatch.observer/filing/0001493152-26-022704.json","markdown":"https://secwatch.observer/filing/0001493152-26-022704.md","text":"https://secwatch.observer/filing/0001493152-26-022704.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226022704/0001493152-26-022704-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226022704/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T20:02:50.753578+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}